Augmented passive immunotherapy with p4 peptide improves phagocyte activity in severe sepsis

Shock

Volumn 46, Issue 6, 2016, Pages 635-641

  Morton, Ben ^a,b   Mitsi, Elena ^b   Pennington, Shaun H ^b,c   Reine, Jesus ^b   Wright, Angela D ^b,d   Parker, Robert ^a,b   Welters, Ingeborg D ^c   Blakey, John D ^a,b   Rajam, Gowrisankar ^e   Ades, Edwin W ^e   Ferreira, Daniela M ^b   Wang, Duolao ^b   Kadioglu, Aras ^c   Gordon, Stephen B ^b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Local Comprehensive Research Network   (United Kingdom)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Bacterial infection; innate immunity; neutrophil biology

Indexed keywords

P4 PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; OLIGOPEPTIDE; PEPTIDE P4;

ADULT; AGED; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HOSPITAL ADMISSION; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PROSPECTIVE STUDY; SEPSIS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHAGOCYTE; PROCEDURES; STREPTOCOCCUS PNEUMONIAE;

AGED; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNIZATION, PASSIVE; MALE; MIDDLE AGED; NEUTROPHILS; OLIGOPEPTIDES; PHAGOCYTES; PHAGOCYTOSIS; PROSPECTIVE STUDIES; SEPSIS; STREPTOCOCCUS PNEUMONIAE;

EID: 84980357070     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000715     Document Type: Article

References (35)

1. ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, et al.: Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371:1496-1506, 2014.
2. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, et al.: Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372(14):1301-1311, 2015.
3. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, et al.: A randomized trial of protocol-based care for early septic shock. N Engl J Med 370(18):1683- 1693, 2014.
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med 41(2):580-637, 2013.
5. The antibiotic alarm. Nature 495(7440):141, 2013.
6. Morton B, Pennington SH, Gordon SB: Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. Expert Rev Respir Med 8:587-596, 2014.
7. Rajam G, Phillips DJ, White E, Anderton J, Hooper CW, Sampson JS, Carlone GM, Ades EW, Romero-Steiner S: A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization. Microb Pathog 44(3):186-196, 2008.
8. Rajam G, Skinner J, Melnick N, Martinez J, Carlone GM, Sampson JS, Ades EW: A 28-aa pneumococcal surface adhesin A-derived peptide, P4, augments passive immunotherapy and rescues mice from fatal pneumococcal infection. J Infect Dis 199(8):1233-1238, 2009.
9. Melnick N, Rajam G, Carlone GM, Sampson JS, Ades EW: Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model. Clin Vaccine Immunol 16(6):806-810, 2009.
10. Rajam G, Sampson J, Carlone GM, Ades EW: An augmented passive immune therapy to treat fulminant bacterial infections. Recent Pat Antiinfect Drug Discov 5(2):157-167, 2010.
11. Rajam G, Bangert M, Hammons GM, Melnick N, Carlone GM, Sampson JS, Ades EW: P4 peptide therapy rescues aged mice from fatal pneumococcal sepsis. Clin Vaccine Immunol 17(11):1823-1824, 2010.
12. Rajam G, Hammons GM, Carlone GM, Sampson JS, Ades EW: A novel innate immune-enhancement strategy combined with IVIG rescues mice from fatal Staphylococcus aureus septicemia. Int J Microbiol 2011:725483, 2011.
13. Weeks JN, Boyd KL, Rajam G, Ades EW,McCullers JA: Immunotherapy with a combination of intravenous immune globulin and p4 peptide rescues mice from postinfluenza pneumococcal pneumonia. Antimicrob Agents Chemother 55(5):2276-2281, 2011.
14. Bangert M, Bricio-Moreno L, Gore S, Rajam G, Ades EW, Gordon SB, Kadioglu S: P4-mediated antibody therapy in an acute model of invasive pneumococcal disease. J Infect Dis 205(9):1399-1407, 2012.
15. Bangert M, Wright AK, Rylance J, Kelly MJ, Wright AD, Carlone GM, Sampson JS, Rajam G, Ades EW, Kadioglu A, et al.: Immunoactivating peptide P4 augments alveolar macrophage phagocytosis in two diverse human populations. Antimicrob Agents Chemother 57:4566-4569, 2013.
16. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12):862-874, 2013.
17. Levy MM, Fink MP,Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31(4):1250-1256, 2003.
18. LevyMM, Dellinger RP, Townsend SR, Linde-Zwirble WT,Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, et al.: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 38(2):367-374, 2010.
19. Demaret J, Venet F, Friggeri A, Cazalis M-A, Plassais J, Jallades L, Malcus C, Poitevin-Later F, Textoris J, Lepape A, et al.: Marked alterations of neutrophil functions during sepsis-induced immunosuppression. J Leukoc Biol 98:1081- 1090, 2015.
20. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH: Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 13(2):165-169, 2006.
21. VanderVen BC, Yates RM, Russell DG: Intraphagosomal measurement of the magnitude and duration of the oxidative burst. Traffic 10(4):372-378, 2009.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40(5):373-383, 1987.
23. Morton B, Nagaraja S, Collins A, Pennington SH, Blakey JD: A retrospective evaluation of critical care blood culture yield do support services contribute to the "weekend effect"? PLoS One 10(10):e0141361, 2015.
24. Martins PS, Brunialti MKC, Martos LSW, Machado FR, AssunçaoMS, Blecher S, Salomao R: Expression of cell surface receptors and oxidative metabolism modulation in the clinical continuum of sepsis. Crit Care 12(1):R25, 2008.
25. Boomer JS, Green JM, Hotchkiss RS: The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer? Virulence 5(1):45-56, 2013.
26. Shindo Y, Unsinger J, Burnham C-A, Green JM, Hotchkiss RS: Interleukin 7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsisinduced immunosuppression. Shock 43:334-343, 2015.
27. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018-1028, 2006.
28. Summers C, Singh NR, White JF, Mackenzie IM, Johnston A, Solanki C, Balan KK, Peters AM, Chilvers ER: Pulmonary retention of primed neutrophils: A novel protective host response, which is impaired in the acute respiratory distress syndrome. Thorax 69(7):623-629, 2014.
29. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM: Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4(4):415-422, 1997.
30. Song JY, Moseley MA, Burton RL, Nahm MH: Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 19(3):412-425, 2013.
31. Yates RM, Hermetter A, Russell DG: The kinetics of phagosome maturation as a function of phagosome/lysosome fusion and acquisition of hydrolytic activity. Traffic 6(5):413-420, 2005.
32. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138-150, 2003.
33. Drifte G, Dunn-Siegrist I, Tissières P, Pugin J: Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med 41(3):820-832, 2013.
34. Metzgar D, Zampolli A.: The M protein of group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence 2(5):402-412, 2011.
35. BrunerM, JamesA,Beall B, CarloneGM,Ades E, Johnson S, Guarner J, Sampson J: Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine. Vaccine 21(21-22):2698-2703, 2003.